3rd Line Therapy - How do you Choose the Right Thing at the Right Time?
This is the second of two parts for the South Asia iCMLf Regional Discussion Group held on the 21st of May 2025.
Regional Expert
Assistant Professor Stalin Bala Chowdry
Mahatma Ghandi Cancer Hospital and Research Institute,
Visakhapatnam, India
International Expert
Dr Kendra Sweet
Moffitt Cancer Center,
Tampa, USA
View the second part of this discussion group: Choice of TKI in Newly Diagnosed CML Patients
See all our 2025 South Asia Regional Discussion Groups on YouTube
Find all our South Asia Regional Discussion Groups on YouTube
00:00 Introduction
00:54 Case1: 30yo male loses deep molecular response after almost 8 years on Imatinib, does not tolerate Dasatinib
06:44 Discussion of case 1
16:07 Case 2: 26yo female loses deep molecular response after 5 years on Imatinib, does not respond to Nilotinib or Dasatinib
20:40 Discussion of case 2
27:08 General questions and discussion
48:10 Thanks and Farewell
